Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 1142524 in diabetic kidney disease
2017-000656-26Phase 2Completed
- Sponsor
- Bayer
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) comparing BAY 1142524 with Placebo (2 arms). Primary endpoint: Change in urinary albumin-to-creatinine ratio (UACR). Started Oct 2017; status: completed.
02
Drugs
fulacimstat
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-000656-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000656-26.